Alvotech and Cipla Collaborate to Ensure Access to Biosimilars in South Africa
Shots:
- Alvotech and Cipla entered an exclusive partnership to provide patients with better access to high quality and cost-effective biosimilar medicines in South Africa
- Alvotech will be responsible for the development and supply of the products and Cipla will be responsible for the registration and commercialization
- The biosimilar portfolio will include five biosimilars- two for oncology and three for treating auto-immune diseases
Ref: Alvotech | Image: Formycon
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
